MGC Pharmaceuticals Limited board also advises that Mr. Evan Hayes has resigned from his position as a non-executive director of the Company, effective 1 January 2023, as part of the Company's transition to a dedicated life sciences pharmaceuticals company. As a result of Mr. Hayes' departure, MGC's board will be reduced to 5 directors, with the Company continuing to evaluate the composition of the board over the next 6 months to ensure that it reflects its position as a European based life sciences pharmaceutical company. The Board would like to thank Mr. Hayes for his valued contribution during his tenure on the board, and wish him well for the future.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.35 AUD | -5.41% | -6.67% | -26.32% |
07/05 | Argent BioPharma Reports CFO Appointment | MT |
07/05 | Argent BioPharma shares begin trading on OTCQB Venture Market | AN |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.32% | 11.12M | |
+37.29% | 6.02B | |
-21.28% | 4.19B | |
+4.52% | 3.25B | |
-18.16% | 2.87B | |
-7.70% | 2.37B | |
+41.50% | 1.89B | |
-4.05% | 1.58B | |
-15.56% | 1.54B | |
-14.62% | 1.5B |
- Stock Market
- Equities
- RGT Stock
- MXC Stock
- News Argent BioPharma Limited
- MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director